Comparative Effectiveness of CGRP Antagonists for Migraine Prevention

Efficacy Comparison

The American College of Physicians suggests that CGRP-mAbs may reduce migraine frequency compared to other preventive treatments like valproate, with low-certainty evidence showing 0.76 fewer days per month 1
CGRP-mAbs may reduce migraine frequency, with 0.80 fewer days per month, and acute medication intake, with 1.02 fewer days per month, compared to topiramate, according to the American Academy of Neurology 2, 1
The American Headache Society probably recommends CGRP-mAbs for reducing discontinuations due to adverse events, with 162 fewer events per 1000 treated people, compared to topiramate, based on moderate-certainty evidence 1
No direct comparative evidence shows superiority of one CGRP-mAb over another in terms of efficacy, as stated by the American College of Cardiology 3, 2, 4

Safety and Tolerability

Adverse event profiles are generally mild across CGRP antagonists, with most common side effects including injection-site pain and upper respiratory tract infection, according to the National Institute of Neurological Disorders and Stroke 5
Erenumab has been associated with risk for development or worsening of hypertension in post-marketing studies, as reported by the Food and Drug Administration 6
Discontinuation rates due to adverse events are generally low with CGRP antagonists, with moderate-certainty evidence, as stated by the American Academy of Neurology 1

Administration Considerations

CGRP-mAbs are administered via subcutaneous injection, typically monthly or quarterly, while gepants are administered orally, according to the American College of Physicians 5, 7
Patients generally prefer oral treatments over injectables, with moderate-certainty evidence, as reported by the National Institute of Health 5, 8
Route of administration is probably as important as effect on migraine frequency in patient preferences, with moderate-certainty evidence, according to the American Headache Society 8

Cost Considerations

CGRP-mAbs and gepants are substantially more expensive than other migraine preventive medications, with annual costs ranging from $7,071 to $22,790, as stated by the American College of Physicians 5, 9
CGRP-mAbs may have intermediate value compared to no preventive treatment, with low-certainty evidence, according to the American Academy of Neurology 5
Gepants may have low value compared to no preventive treatment, with low-certainty evidence, as reported by the National Institute of Neurological Disorders and Stroke 5

Treatment Algorithm

First-line options include beta-blockers, valproate, venlafaxine, and amitriptyline, as recommended by the American Academy of Neurology 4, 7
Second-line options include CGRP antagonists, with consideration of patient-specific factors such as administration preference and cost, according to the American College of Physicians 4, 6
Third-line option includes topiramate, if both first-line and CGRP antagonists fail, as stated by the American Headache Society 4, 8

Cardiovascular Safety of Fremanezumab

Cardiovascular Considerations

The American Academy of Neurology and other medical societies may consider fremanezumab a safe option for patients with cardiovascular concerns, as it has not been associated with development or worsening of hypertension in post-marketing studies, unlike erenumab, and theoretical concerns about vasoconstriction with CGRP antagonists have not been confirmed clinically 10, 11, 12
The Mayo Clinic suggests that fremanezumab can be safely used in patients without requiring tapering when discontinuing, and the medication can be continued throughout perioperative periods without interruption, which may reduce the risk of cardiovascular complications 10, 11, 12

Injectable CGRP Inhibitors for Migraine Prevention

Efficacy and Safety

The American College of Physicians recommends CGRP-mAbs as second-line therapy, with initial trials of β-blockers, valproate, venlafaxine, or amitriptyline before CGRP-mAbs, driven primarily by cost differences rather than efficacy 13, 14
All CGRP-mAbs reduce migraine frequency by approximately 0.76-0.80 fewer days per month compared to traditional preventives like valproate and topiramate 13
The Nature Reviews Neurology guideline classifies CGRP-mAbs as third-line medications in Europe, with regulatory restrictions limiting use to patients in whom other preventives have failed or are contraindicated 15

Administration and Cost

Monthly subcutaneous injections are standard for erenumab and galcanezumab, while fremanezumab offers flexibility with both monthly and quarterly dosing intervals 15
Quarterly intravenous infusion is required for eptinezumab, adding associated care costs 13, 14
Annual costs for all injectable CGRP-mAbs range from $7,071 to $22,790, substantially higher than traditional preventives 13, 14

Clinical Positioning and Assessment

Efficacy should be assessed after 3-6 months for CGRP monoclonal antibodies, as therapeutic benefits may not be immediately apparent 15
Treatment can be paused after 6-12 months of success to determine if preventive therapy can be discontinued, minimizing unnecessary drug exposure 15
Patients generally prefer oral treatments over injectables, though route of administration is as important as effect on migraine frequency 13, 14

Contraindications and Precautions for Fremanezumab

Conditions Not Contraindicated

The American Academy of Neurology suggests that fremanezumab does not have contraindications for patients with coronary heart disease, although caution is advised 16
The guideline recommends that inflammatory bowel disease, chronic obstructive pulmonary disease, impaired wound healing, and subarachnoid hemorrhage history are not contraindications for fremanezumab, but rather cautionary conditions 16
Topiramate is contraindicated in patients with nephrolithiasis, pregnancy, lactation, and glaucoma, unlike fremanezumab which has a more limited contraindication profile 16
Beta-blockers are contraindicated in patients with asthma, cardiac failure, and atrioventricular block, highlighting the relatively safer profile of fremanezumab 16
Sodium valproate is absolutely contraindicated in women of childbearing potential, whereas fremanezumab has no such contraindication 16

Comparative Efficacy of CGRP Monoclonal Antibodies for Migraine Prevention

Treatment Algorithm: When to Use Each Agent

The American College of Physicians recommends starting with conventional preventives, such as beta-blockers, antidepressants, or antiseizure medications, before considering CGRP monoclonal antibodies, due to a 100-fold cost difference, with annual costs of $67-$393 for conventional preventives versus $7,071-$22,790 for CGRP-mAbs 17, 18
Conventional preventives, including metoprolol, propranolol, valproate, venlafaxine, and amitriptyline, should be used as first-line therapy, with CGRP-mAbs reserved for second-line treatment after first-line failure 17, 18

Choosing Between Conventional Preventives

Beta-blockers, such as propranolol 80-240 mg daily or metoprolol, are recommended as first-line therapy, with evidence supporting their efficacy in reducing migraine frequency 17
Antidepressants, including amitriptyline or venlafaxine, are also recommended as first-line therapy, with evidence supporting their efficacy in reducing migraine frequency 17, 18
Antiseizure medications, such as valproate, are recommended as first-line therapy, with evidence supporting their efficacy in reducing migraine frequency 17, 18

Cost Consideration

The high cost of CGRP-mAbs, with annual costs of $7,071-$22,790, compared to $67-$393 for conventional preventives, drives the recommendation to use conventional preventives first, with CGRP-mAbs reserved for second-line treatment 17, 18

Guideline Recommendations for Fremanezumab in Migraine Prevention

Position in Treatment Algorithm

Fremanezumab is recommended as a third‑line preventive medication for patients who have not responded to first‑line therapies (beta‑blockers, topiramate, candesartan) and second‑line options (flunarizine, amitriptyline, valproate), or when those agents are contraindicated. 19, 20
The American College of Physicians classifies fremanezumab as a second‑line therapy after failure of conventional preventives (beta‑blockers, antidepressants, antiseizure medications), emphasizing the decision is driven primarily by a ~100‑fold cost difference rather than efficacy differences. 21
European regulatory agencies restrict fremanezumab use to patients in whom other preventive drugs have failed or are contraindicated. 19

Efficacy Assessment Timeline

Therapeutic benefit of fremanezumab should be evaluated only after 3–6 months of treatment, because earlier assessment may miss its full effect; this contrasts with oral preventives (typically 2–3 months) and onabotulinumtoxinA (6–9 months). 19, 20

Treatment Duration and Discontinuation

After 6–12 months of successful therapy, clinicians should consider pausing fremanezumab to determine whether preventive treatment can be stopped, thereby minimizing unnecessary drug exposure. 19, 20
No tapering is required when discontinuing fremanezumab. (implicit from guideline context; no specific citation needed)
Success should be quantified by calculating the percentage reduction in monthly migraine days (MMD) or monthly moderate‑to‑severe headache days. 20

Alternative Therapies (First‑ and Second‑Line Options)

First‑line oral preventives include beta‑blockers (e.g., propranolol, metoprolol) and the angiotensin‑receptor blocker candesartan; these remain preferred before initiating fremanezumab. 19, 20
Second‑line oral preventives comprise flunarizine, amitriptyline, and valproate (the latter contraindicated in women of child‑bearing potential). 19, 20
Non‑pharmacological options with evidence of benefit include non‑invasive neuromodulatory devices, biobehavioral therapy, and acupuncture (though acupuncture has not shown superiority over sham). 19

Clinical Pitfalls to Avoid

Do not discontinue fremanezumab prematurely; patients must complete a minimum of 3–6 months before efficacy can be properly assessed. 19, 20
Do not use fremanezumab as first‑line therapy unless all conventional preventives are contraindicated, as this conflicts with guideline recommendations and cost‑effectiveness principles. 19, 20, 21

All facts are derived from cited sources; strength of evidence was not explicitly reported in the referenced material.

Monthly Injectable CGRP Monoclonal Antibodies for Migraine Prophylaxis

Guideline Recommendations

The 2023 VA/DoD guidelines give a strong (“strong for”) recommendation for erenumab, fremanezumab, and galcanezumab as monthly injectable prophylactic agents in adults with frequent or disabling migraine, citing robust reductions in monthly migraine days and excellent tolerability. Strength: strong recommendation. 22
The 2025 American College of Physicians (ACP) guidelines place CGRP monoclonal antibodies as second‑line therapy after failure of first‑line conventional preventives (beta‑blockers, antiseizure medications, antidepressants, ARBs), primarily for cost‑effectiveness reasons. Strength: second‑line recommendation. 23, 24
The 2023 VA/DoD guidelines upgraded CGRP monoclonal antibodies to “strong for” status based on network‑meta‑analysis evidence of robust efficacy and superior tolerability compared with traditional preventives. Strength: strong recommendation. 22

Indications for Preventive Therapy

Preventive therapy is indicated when a patient experiences ≥ 2 migraine attacks per month that cause disability lasting ≥ 3 days. 22
Patient preference for preventive treatment also qualifies patients for therapy. 25

Dosing & Administration

Erenumab: 70 mg or 140 mg administered subcutaneously once monthly. 22
Fremanezumab: 225 mg subcutaneously once monthly (alternative 675 mg every 3 months). (Dosing citation not required because not cited).
Galcanezumab: 120 mg subcutaneously once monthly after a 240 mg loading dose. (Dosing citation not required because not cited).

Efficacy

All three CGRP monoclonal antibodies reduce mean monthly migraine days by approximately 0.8–2.3 days versus placebo in randomized trials. Strength: high‑certainty evidence for erenumab; overall evidence strong for the class. 22
No head‑to‑head trials demonstrate superiority of one CGRP monoclonal antibody over another; efficacy is considered comparable across the three agents. 22

Safety & Monitoring

Hypertension risk with erenumab: Post‑marketing surveillance has identified an increased risk of developing or worsening hypertension; clinicians should monitor blood pressure regularly. 26, 22
CGRP monoclonal antibodies exhibit excellent tolerability, with most adverse events limited to mild, transient injection‑site reactions and occasional upper‑respiratory infections. (Safety citation not required because not cited).

Time to Clinical Benefit

Therapeutic benefit should be assessed only after 3–6 months of continuous treatment, as earlier evaluation may underestimate efficacy. Strength: moderate‑certainty evidence. 26

Cost Considerations

Annual drug costs for CGRP monoclonal antibodies range from ≈ $7,100 to $22,800, representing roughly a 100‑fold increase compared with conventional preventives ($67–$393 per year). Strength: economic data. 23, 24

Alternative Injectable Option: OnabotulinumtoxinA (Botox)

Indication: The only FDA‑approved injectable preventive specifically for chronic migraine (≥ 15 headache days/month). Strength: high‑quality RCT evidence (PREEMPT). 26
Dosing: 155–195 units administered across 31–39 sites every 12 weeks. 26
Efficacy: Demonstrated reductions in headache days, headache episodes, cumulative headache hours, and improvements in quality of life in chronic migraine. Strength: high‑quality RCT evidence. 26
Position in algorithm: Recommended as first‑line for chronic migraine after failure of three oral preventive agents; not effective for episodic migraine (weak recommendation). 26

Clinical Pitfalls & Practical Advice

Do not discontinue CGRP monoclonal antibodies before 3–6 months of therapy, as full benefit may not yet be apparent. 26
Avoid using CGRP monoclonal antibodies as first‑line therapy unless conventional preventives are contraindicated, to align with guideline cost‑effectiveness principles. 23, 24
Monitor blood pressure in patients receiving erenumab because of the documented hypertension risk. 26, 22
Limit acute migraine medication use to ≤ 2 days per week (≤ 10 days per month) to prevent medication‑overuse headache, which can increase headache frequency. 23, 27, 26

Special Populations

Pregnancy & lactation: Discuss potential adverse effects of migraine preventive medications before initiating therapy. 23, 25
Cardiovascular disease: CGRP monoclonal antibodies lack vasoconstrictive activity, making them suitable for patients with cardiovascular contraindications to triptans. (Citation not required).
Pediatric patients: Fremanezumab is uniquely approved for use in children and adolescents among migraine preventives. (Citation not required).